Abstract
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-27 |
| Number of pages | 5 |
| Journal | Current Osteoporosis Reports |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2010 |
Fingerprint
Keywords
- BMD
- BMP
- Osteoporosis
- PTH
- Sclerostin
- Wnt
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
Cite this
Anabolic therapies. / Lane, Nancy E; Silverman, Stuart L.
In: Current Osteoporosis Reports, Vol. 8, No. 1, 03.2010, p. 23-27.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anabolic therapies
AU - Lane, Nancy E
AU - Silverman, Stuart L.
PY - 2010/3
Y1 - 2010/3
N2 - The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.
AB - The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.
KW - BMD
KW - BMP
KW - Osteoporosis
KW - PTH
KW - Sclerostin
KW - Wnt
UR - http://www.scopus.com/inward/record.url?scp=77953621455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953621455&partnerID=8YFLogxK
U2 - 10.1007/s11914-010-0005-4
DO - 10.1007/s11914-010-0005-4
M3 - Article
C2 - 20425087
AN - SCOPUS:77953621455
VL - 8
SP - 23
EP - 27
JO - Foodborne Pathogens and Disease
JF - Foodborne Pathogens and Disease
SN - 1744-165X
IS - 1
ER -